Hims & Hers: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Nov. 9, 2026, Hims & Hers (NYSE:HIMS) announced an intentional pullback in marketing spend ahead of expanding its medication catalog. Trading short-term subscriber growth for a broader product catalog positions the platform to capture peak consumer demand in early 2027. This disciplined focus on multicategory scale lays the groundwork for durable revenue expansion across global markets. Three things management said stand out. Management intentionally slowed third-quarter customer acquisition spending to complete expansion of its product lineup before annual weight-loss interest peaks in January. Accepting a temporary sequential drop of 100,000 subscribers preserves capital to launch multi-month subscriptions at lower consumer price points. Securing access to branded glucagon-like peptide-1 (GLP-1) treatments, including Zepbound and Foundayo from Eli Lilly alongside existing Novo Nordisk products, broadens consumer choice on the digital platform. Management expects offering a complete therapeutic catalog to lower customer acquisition costs and boost retention over time. Continue reading